ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.729,40
-0,73%
S&P 500
5.267,84
-0,74%
US Dollar vs BRL
5,1441
-0,16%
Bitcoin
67.538,51
-2,26%
Brent Oil
81,27
-0,32%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Solid Biosciences Inc (SLDB)

  7. Solid Biosciences Inc (SLDB) Notícias

SLDB

Solid Biosciences (SLDB)

Solid Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SLDB
DataHoraFonteTítuloCódigoCompanhia
20/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLDBSolid Biosciences Inc
15/05/202409:26Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SLDBSolid Biosciences Inc
15/05/202408:52GlobeNewswire Inc.Solid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
15/05/202408:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLDBSolid Biosciences Inc
07/05/202408:00GlobeNewswire Inc.Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:SLDBSolid Biosciences Inc
06/05/202419:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
02/05/202417:05GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
01/04/202408:45GlobeNewswire Inc.Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
27/03/202408:00GlobeNewswire Inc.Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumNASDAQ:SLDBSolid Biosciences Inc
13/03/202408:44GlobeNewswire Inc.Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
07/03/202409:00GlobeNewswire Inc.Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDNASDAQ:SLDBSolid Biosciences Inc
06/03/202410:00GlobeNewswire Inc.Solid Biosciences to Participate at Upcoming Investor ConferencesNASDAQ:SLDBSolid Biosciences Inc
30/01/202418:09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLDBSolid Biosciences Inc
19/01/202421:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/01/202410:50Dow Jones NewsSolid Biosciences Gets Orphan Drug Designation for SGT-003NASDAQ:SLDBSolid Biosciences Inc
16/01/202410:00GlobeNewswire Inc.Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
12/01/202419:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SLDBSolid Biosciences Inc
08/01/202409:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLDBSolid Biosciences Inc
08/01/202409:09GlobeNewswire Inc.Solid Biosciences Announces $109 Million Private PlacementNASDAQ:SLDBSolid Biosciences Inc
04/01/202410:00GlobeNewswire Inc.Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
07/12/202312:49Dow Jones NewsSolid Biosciences Shares Jump After FDA Fast-Tracks SGT-0003NASDAQ:SLDBSolid Biosciences Inc
07/12/202310:00GlobeNewswire Inc.Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003NASDAQ:SLDBSolid Biosciences Inc
22/11/202310:00GlobeNewswire Inc.Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
15/11/202310:51IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:SLDBSolid Biosciences Inc
14/11/202318:05GlobeNewswire Inc.Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
09/11/202310:00GlobeNewswire Inc.Solid Biosciences to Participate at Jefferies London Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
08/11/202318:17GlobeNewswire Inc.Solid Biosciences Provides Third Quarter Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
02/10/202309:00GlobeNewswire Inc.Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical OfficerNASDAQ:SLDBSolid Biosciences Inc
31/08/202309:00GlobeNewswire Inc.Solid Biosciences to Participate in Citi’s 18th Annual BioPharma ConferenceNASDAQ:SLDBSolid Biosciences Inc
14/08/202317:17GlobeNewswire Inc.Solid Biosciences Provides Second Quarter Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SLDB

Seu Histórico Recente

BIT
BMPS
Banca Monte Dei Paschi D...
BIT
SPMR
Saipem
TG
TGX
Talga
NASDAQ
BSMW
Invesco BulletShares 203...
TG
5LA1
American Lithium
COIN
CNBBUST
Carbon Neutrality Blockchain
LBNK
SAFEREUMUSDT
Safereum
EU
PHG
Lyxor STOXX Europe 600 P...
LSE
10BE
DBI
LJM3
INXTMSCI USA INTE1CDL
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados